Heart Rate Variability in Hyperthyroidism: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Valentin Brusseau
,
Igor Tauveron
,
Reza Bagheri
,
Ukadike Chris Ugbolue
,
Valentin Magnon
,
Jean-Baptiste Bouillon-Minois
,
Valentin Navel
,
Frédéric Dutheil

Cardiovascular effects of thyroid hormones may be measured through heart rate variability (HRV). Hyperthyroidism is associated with a decreased HRV, which may be explained by the effect of thyroid hormones and thyroid-stimulating hormone (TSH). The increased sympathetic and decreased parasympathetic activity may have clinical implications.

  • thyroid
  • biomarker
  • autonomic nervous activity
  • prevention

1. Introduction

The thyroid gland and the autonomic nervous system are closely linked by their control center, the hypothalamus, and by their effects on the cardiovascular system [1][2]. Hyperthyroidism is a common global health problem and a risk factor for cardiovascular mortality [3]. One of the main complications of hyperthyroidism is cardiac arrhythmias, most often supraventricular, and may be caused by sympathovagal imbalance. Indeed, the clinical manifestations of hyperthyroidism (tachycardia, palpitation, systolic arterial hypertension) suggest β-adrenergic stimulation and dysautonomia [4][5][6][7]. Dysautonomia means a change in the function of the autonomic nervous system can negatively affect the health of a person [8]. Sympathovagal imbalance is associated with an increased risk of ventricular arrhythmias and cardiac mortality [9][10], which can be measured by the study of heart rate variability (HRV). HRV is the variation between two consecutive heartbeats related to the continuous interaction between the two arms of the autonomic nervous system, sympathetic and parasympathetic [11]. HRV is a sensitive, quantitative and non-invasive tool for the study of autonomic nerve function [12][13][14]. High HRV suggests an adaptable and dynamic autonomic nervous system [15]. Low HRV is a marker of cardiovascular risk and represents an abnormal or restricted ability of the autonomic nervous system to maintain homeostasis [16][17]. Indeed, the degree and type of autonomic imbalance and its contribution to cardiovascular abnormalities in hyperthyroidism are not fully understood [18]. Many studies have shown a tendency for HRV depression with an impaired cholinergic reserve, providing a logical explanation for the increased sympathetic activity in hyperthyroidism. If these results are reproducible, it may contribute to the understanding of the susceptibility to cardiac arrhythmias in hyperthyroidism and indicate possible early therapeutic intervention. In addition, there is no consensus on the decreased levels of HRV parameters in hyperthyroidism. Two biochemical entities are distinguished: overt hyperthyroidism, with a prevalence of 0.5% of the general population [19], and subclinical hyperthyroidism, with 1.8% [20].

2. Heart Rate Variability in Hyperthyroidism

There is a decreased HRV in patients with hyperthyroidism, which may be explained by the deleterious effect of thyroid hormones and TSH. The increased sympathetic and decreased parasympathetic activity may have clinical implications. Some other factors, such as age or BMI, should also be considered in a clinical perspective.

2.1. Deleterious Effects of Thyroid Hyperfunction on HRV

The cardiovascular effects of thyroid hormones occur either directly through nuclear receptors [4] or indirectly by the sympathoadrenergic system [21]. Excess thyroid hormones has a direct chronotropic effect on the sinus node [22][23]. Changes in HRV are not only related to chronotropic effects. For example, propanolol is one of the most effective treatments for heart rate and did not alter HRV parameters [24]. Hyperthyroidism is characterized by a hyperkinetic state, similar to that induced by catecholamine excess [6], but serum and urine catecholamine levels are normal or decreased in hyperthyroidism [25][26]. The increased density and sensitivity of β-adrenergic receptors to catecholamines in hyperthyroidism may explain the increase in sympathetic activity [27][28][29]. More specifically, it showed a sympathovagal imbalance in hyperthyroidism. Vagal inhibition was more intense than increased sympathetic activity, with a greater decrease in HF power than LF power. As expected, TP decreased markedly (cardiac vagal control) as HF is its main contributor—two-thirds—whereas LF and VLF contribute one-third [12][30]. HRV is decreased mainly because of a large decrease in vagal activity [12][30]. Then, RR intervals decreased in patients with subclinical hyperthyroidism, and further decreased in overt hyperthyroidism. Moreover, an increase in fT3 and fT4, and a decrease in TSH, were related to a decrease in RR intervals. HRV parameters may indirectly reflect the severity of hyperthyroidism [31]. Subclinical hyperthyroidism appears to be an intermediate cardiovascular state between euthyroidism and overt hyperthyroidism, a continuum related to thyroid hormone excess [32][33]. An increase in sympathetic activity seems to be the first modification of the sympathovagal balance, which may be due to the decrease in TSH [33][34][35][36][37][38]. However, these results should be treated with caution because those studies only reported some selected HRV parameters. This parasympathetic inhibition may be due to the action of thyroid hormones on centers regulating autonomic functions [39][40] and on cardiac M2-muscarinic receptors [28], and increased adrenergic reactivity may be due to the main effects of abnormal TSH concentrations [41].

2.2. Clinical Implications

Decreased vagal tone and increased sympathetic activity in hyperthyroidism have important clinical implications. Thyroid hormones play a role in arrhythmogenesis with a risk of atrial fibrillation [42], which may be related to decreased HRV [43]. For example, a high incidence of supraventricular arrhythmias has been reported in overt hyperthyroidism women with very low HRV [31]. Increased sympathetic modulation and vagal inhibition were observed before the onset of paroxysmal atrial fibrillation [44], which may explain the increased prevalence of atrial fibrillation in these patients. A decreased HRV should strengthen the idea of treating subclinical hyperthyroidism [45]. However, early antithyroid therapy remains contradictory [34][45]. Indeed, if antithyroid treatment allows reversibility of HRV abnormalities, it would constitute an additional argument to treat subclinical hyperthyroidism in order to avoid rhythmic complications in these patients. Patients with decreased vagal tone are more susceptible to cardiovascular disease [46][47] with increased cardiac morbidity and mortality without apparent heart muscle damage [48]. It has also been shown that decreased TP predicts an increased risk of sudden cardiac death [49] and total cardiac mortality [50], that decreased LF is a strong predictor of sudden death independently of other variables [45], and that decreased VLF is an indicator of increased cardiac mortality in patients after myocardial infarction [51][52]. These data suggest that HRV parameters may be a marker of increased mortality in hyperthyroid patients. Physical activity and hyperthyroidism have the same effects on HRV, i.e., a concomitant sympathetic activation and decreased vagal tone [53]. Hence, many hyperthyroid patients are intolerant to exercise due to a reduced ability to increase cardiac output [54][55], in addition to the usual musculoskeletal manifestations of hyperthyroidism [56].

2.3. Other Variables Related to HRV in Hyperthyroidism

Age was associated with higher RR, TP, HFnu, and lower LFnu and LF/HF ratio. Thus, age was linked with an increased HRV in hyperthyroidism. However, in the general population, older age is associated with a decrease in HRV [57][58] due to decreased parasympathetic regulation [59]. Younger patients had more severe hyperthyroidism and a high prevalence of Graves’ disease [60]. There is an increase in systolic blood pressure was associated with lower RMSSD, i.e., a decrease in parasympathetic activity. Conflicting results have been reported in the general population, with elevated blood pressure associated with either an increase [61] or a decrease [62] in HRV. It has also been suggested that decreased autonomic nerve function precedes the development of clinical hypertension [63]. Increased BMI was associated with higher RR intervals, TP, LF, HF and VLF power, and lower LF/HF ratio, i.e., increasing HRV with increased parasympathetic activity. However, an increase in BMI is associated with lower HRV [64][65]. Hyperthyroid patients often presented a weight loss, resulting in a significantly lower mean BMI than healthy controls. In malnourished subjects, there is a decrease in HFnu with an increase in LFnu and LF/HF ratio [66]; hence, normalization of BMI may improve HRV. BMI does not distinguish between lean and fat tissue [67][68]. Interestingly, HRV may be more related to body composition than to BMI, and especially to body fat [69][70], which is lowered in hyperthyroid patients [71].

3. Conclusions

HRV is markedly decreased in hyperthyroid patients. Increased sympathetic and decreased parasympathetic activity may be explained by the deleterious cardiovascular effects of thyroid hormones. The benefits of HRV assessment in the evaluation and monitoring of the severity of hyperthyroidism should be further investigated, given its potential as a noninvasive, reliable, and pain-free measurement.

This entry is adapted from the peer-reviewed paper 10.3390/ijerph19063606

References

  1. Bhat, A.N.; Kalsotra, L.; Yograj, S. Autonomic reactivity with altered thyroid status. JK Sci. 2007, 9, 70–74.
  2. Reeves, J.W.; Fisher, A.J.; Newman, M.G.; Granger, D.A. Sympathetic and hypothalamic-pituitary-adrenal asymmetry in generalized anxiety disorder: Sympathetic and HPA asymmetry in GAD. Psychophysiology 2016, 53, 951–957.
  3. Parle, J.V.; Maisonneuve, P.; Sheppard, M.C.; Boyle, P.; Franklyn, J.A. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study. Lancet 2001, 358, 861–865.
  4. Klein, I.; Ojamaa, K. Thyroid hormone and the cardiovascular system: From theory to practice. J. Clin. Endocrinol. Metab. 1994, 78, 1026–1027.
  5. Kahaly, G.J.; Dillmann, W.H. Thyroid hormone action in the heart. Endocr. Rev. 2005, 26, 704–728.
  6. Florea, V.G.; Cohn, J.N. The autonomic nervous system and heart failure. Circ. Res. 2014, 114, 1815–1826.
  7. Liggett, S.B.; Shah, S.D.; Cryer, P.E. Increased fat and skeletal muscle j3-adrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrine in vivo in experimental human thyrotoxicosis. J. Clin. Investig. 1989, 83, 803–809.
  8. Goldstein, D.S. Dysautonomias: Clinical disorders of the autonomic nervous system. Ann. Intern. Med. 2002, 137, 753.
  9. Zaidi, M.; Robert, A.; Fesler, R.; Derwael, C.; Brohet, C. Dispersion of ventricular repolarisation: A marker of ventricular arrhythmias in patients with previous myocardial infarction. Heart 1997, 78, 371–375.
  10. Algra, A.; Tijssen, J.G.; Roelandt, J.R.; Pool, J.; Lubsen, J. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 1993, 88, 180–185.
  11. Cygankiewicz, I.; Zareba, W. Heart rate variability. In Handbook of Clinical Neurology; Elsevier: Amsterdam, The Netherlands, 2013; pp. 379–393.
  12. Malik, M.; Bigger, J.T.; Camm, A.J.; Kleiger, R.E.; Malliani, A.; Moss, A.J.; Schwartz, P.J. Heart rate variability: Standards of measurement, physiological interpretation, and clinical use. Eur. Heart J. 1996, 17, 354–381.
  13. Min, K.B.; Min, J.-Y.; Paek, D.; Cho, S.-I.; Son, M. Is 5-minute heart rate variability a useful measure for monitoring the autonomic nervous system of workers? Int. Heart J. 2008, 49, 175–181.
  14. Dutheil, F.; Chambres, P.; Hufnagel, C.; Auxiette, C.; Chausse, P.; Ghozi, R.; Paugam, G.; Boudet, G.; Khalfa, N.; Naughton, G.; et al. ‘Do Well B.’: Design of Well Being monitoring systems. A study protocol for the application in autism. BMJ Open 2015, 5, e007716.
  15. Hufnagel, C.; Chambres, P.; Bertrand, P.R.; Dutheil, F. The need for objective measures of stress in autism. Front. Psychol. 2017, 8.
  16. Boudet, G.; Walther, G.; Courteix, D.; Obert, P.; Lesourd, B.; Pereira, B.; Chapier, R.; Vinet, A.; Chamoux, A.; Naughton, G.; et al. Paradoxical dissociation between heart rate and heart rate variability following different modalities of exercise in individuals with metabolic syndrome: The RESOLVE study. Eur. J. Prev. Cardiolog. 2017, 24, 281–296.
  17. McMillan, D.E. Interpreting heart rate variability sleep/wake patterns in cardiac patients. J. Cardiovasc. Nurs. 2002, 17, 69–81.
  18. Foley, C.M.; McAllister, R.M.; Hasser, E.M. Thyroid status influences baroreflex function and autonomic contributions to arterial pressure and heart rate. Am. J. Physiol. Circ. Physiol. 2001, 280, H2061–H2068.
  19. Garmendia Madariaga, A.; Santos Palacios, S.; Guillén-Grima, F.; Galofré, J.C. The incidence and prevalence of thyroid dysfunction in Europe: A meta-analysis. J. Clin. Endocrinol. Metab. 2014, 99, 923–931.
  20. Hollowell, J.G.; Staehling, N.W.; Flanders, W.D.; Hannon, W.H.; Gunter, E.W.; Spencer, C.A.; Braverman, L.E. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 2002, 87, 489–499.
  21. Johnson, J. Atrial fibrillation and hyperthyroidism. Indian Pacing Electrophysiol. J. 2005, 5, 305–311.
  22. Klein, I.; Danzi, S. Thyroid disease and the heart. Circulation 2007, 116, 1725–1735.
  23. Polikar, R.; Burger, A.G.; Scherrer, U.; Nicod, P. The thyroid and the heart. Circulation 1993, 87, 1435–1441.
  24. Tankeu, A.T.; Azabji-Kenfack, M.; Nganou, C.-N.; Ngassam, E.; Kuate-Mfeukeu, L.; Mba, C.; Dehayem, M.Y.; Mbanya, J.-C.; Sobngwi, E. Effect of propranolol on heart rate variability in hyperthyroidism. BMC Res. Notes 2018, 11, 151.
  25. Levey, G.S.; Klein, I. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. Am. J. Med. 1990, 88, 642–646.
  26. Coulombe, P.; Dussault, J.H.; Letarte, J.; Simard, S.J. Catecholamines Metabolism in Thyroid Diseases. I. Epinephrine Secretion Rate in Hyperthyroidism and Hypothyroidism. J. Clin. Endocrinol. Metab. 1976, 42, 125–131.
  27. Reddy, V.; Taha, W.; Kundumadam, S.; Khan, M. Atrial fibrillation and hyperthyroidism: A literature review. Indian Hear. J. 2017, 69, 545–550.
  28. Maciel, B.C.; Gallo, L.; Neto, J.A.M.; Maciel, L.M.Z.; Alves, M.L.D.; Paccola, G.M.F.; Iazigi, N. The role of the autonomic nervous system in the resting tachycardia of human hyperthyroidism. Clin. Sci. 1987, 72, 239–244.
  29. Insel, P. Adrenergic receptors. Evolving concepts on structure and function. Am. J. Hypertens. 1989, 3 Pt 2, 112–118.
  30. Malliani, A. Heart rate variability: From bench to bedside. Eur. J. Intern. Med. 2005, 16, 12–20.
  31. Tudoran, C.; Tudoran, M.; Vlad, M.; Balas, M.; Ciocarlie, T.; Parv, F. Alterations of heart rate variability and turbulence in female patients with hyperthyroidism of various severities. Niger. J. Clin. Pract. 2019, 22, 1349–1355.
  32. Goichot, B.; Brandenberger, G.; Vinzio, S.; Perrin, E.; Geny, B.; Schlienger, J.L.; Simon, C. Sympathovagal response to orthostatism in overt and in subclinical hyperthyroidism. J. Endocrinol. Investig. 2004, 27, 348–352.
  33. Peixoto de Miranda, É.J.F.; Hoshi, R.A.; Bittencourt, M.S.; Goulart, A.C.; Santos, I.S.; Brunoni, A.R.; Diniz, M.F.H.S.; Ribeiro, A.L.P.; Dantas, E.M.; Mill, J.G.; et al. Relationship between heart rate variability and subclinical thyroid disorders of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Braz. J. Med. Biol. Res. 2018, 51.
  34. Falcone, C.; Matrone, B.; Bozzini, S.; Guasti, L.; Falcone, R.; Benzi, A.; Colonna, A.; Savulescu, I.; Vailati, A.; Pelissero, G. Time-Domain Heart Rate Variability in Coronary Artery Disease Patients Affected by Thyroid Dysfunction. Int. Heart J. 2014, 55, 33–38.
  35. Galetta, F.; Franzoni, F.; Fallahi, P.; Tocchini, L.; Graci, F.; Gaddeo, C.; Rossi, M.; Cini, G.; Carpi, A.; Santoro, G.; et al. Changes in autonomic regulation and ventricular repolarization induced by subclinical hyperthyroidism. Biomed. Pharmacother. 2010, 64, 546–549.
  36. Ngassam, E.; Azabji-Kenfack, M.; Tankeu, A.T.; Mfeukeu-Kuate, L.; Nganou-Gnindjio, C.-N.; Mba, C.; Katte, J.C.; Dehayem, M.Y.; Mbanya, J.C.; Sobngwi, E. Heart rate variability in hyperthyroidism on sub Saharan African patients: A case-control study. BMC Res. Notes 2018, 11, 814.
  37. Portella, R.B.; Pedrosa, R.C.; Coeli, C.M.; Buescu, A.; Vaisman, M. Altered cardiovascular vagal responses in nonelderly female patients with subclinical hyperthyroidism and no apparent cardiovascular disease. Clin. Endocrinol. 2007, 67, 290–294.
  38. Tobaldini, E.; Porta, A.; Bulgheroni, M.; Pecis, M.; Muratori, M.; Bevilacqua, M.; Montano, N. Increased complexity of short-term heart rate variability in hyperthyroid patients during orthostatic challenge. In Proceedings of the 2008 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Vancouver, BC, Canada, 20–25 August 2008; pp. 1988–1991.
  39. Gautam, S.; Tandon, O.P.; Awashi, R.; Sekhri, T.; Sircar, S.S. Correlation of autonomic indices with thyroid status. Indian J. Physiol. Pharmacol. 2003, 47, 164–170.
  40. Straznicky, N.E.; Eikelis, N.; Lambert, E.A.; Esler, M.D. Mediators of sympathetic activation in metabolic syndrome obesity. Curr. Hypertens. Rep. 2008, 10, 440–447.
  41. Petretta, M.; Bonaduce, D.; Spinelli, L.; Vicario, M.L.; Nuzzo, V.; Marciano, F.; Camuso, P.; De Sanctis, V.; Lupoli, G. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur. J. Endocrinol. 2001, 145, 691–696.
  42. Chen, Y.-C.; Chen, S.-A.; Chen, Y.-J.; Chang, M.-S.; Chan, P.; Lin, C.-I. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J. Am. Coll. Cardiol. 2002, 39, 366–372.
  43. Khan, A.A.; Lip, G.Y.H.; Shantsila, A. Heart rate variability in atrial fibrillation: The balance between sympathetic and parasympathetic nervous system. Eur. J. Clin. Investig. 2019, 49, e13174.
  44. Lombardi, F. Autonomic nervous system and paroxysmal atrial fibrillation: A study based on the analysis of RR interval changes before, during and after paroxysmal atrial fibrillation. Eur. Heart J. 2004, 25, 1242–1248.
  45. Kaminski, G.; Makowski, K.; Michałkiewicz, D.; Kowal, J.; Ruchala, M.; Szczepanek, E.; Gielerak, G. The influence of subclinical hyperthyroidism on blood pressure, heart rate variability, and prevalence of arrhythmias. Thyroid 2012, 22, 454–460.
  46. Pal, G.; Pal, P.; Nanda, N. Integrated regulation of cardiovascular functions. In Comprehensive Textbook of Medical Physiology; Jaypee Brothers Medical Publishers: New Delhi, India, 2007; pp. 654–657.
  47. Haensel, A.; Mills, P.J.; Nelesen, R.A.; Ziegler, M.G.; Dimsdale, J.E. The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. Psychoneuroendocrinology 2008, 33, 1305–1312.
  48. Mavai, M.; Singh, Y.R.; Gupta, R.C.; Mathur, S.K.; Bhandari, B. Linear analysis of autonomic activity and its correlation with creatine kinase-MB in overt thyroid dysfunctions. Ind. J. Clin. Biochem. 2018, 33, 222–228.
  49. La Rovere, M.T.; Bigger, J.T., Jr.; Marcus, F.I.; Mortara, A.; Schwartz, P.J. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998, 351, 478–484.
  50. Dekker, J.M.; Crow, R.S.; Folsom, A.R.; Hannan, P.J.; Liao, D.; Swenne, C.A.; Schouten, E.G. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: The ARIC study. Circulation 2000, 102, 1239–1244.
  51. Bigger, J.T., Jr.; Fleiss, J.L.; Steinman, R.C.; Rolnitzky, L.M.; Kleiger, R.E.; Rottman, J.N. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992, 85, 164–171.
  52. Bigger, J.; Fleiss, J.L.; Rolnitzky, L.M.; Steinman, R.C. Frequency domain measures of heart period variability to assess risk late after myocardial infarction. J. Am. Coll. Cardiol. 1993, 21, 729–736.
  53. Tulppo, M.P.; Hughson, R.; Mäkikallio, T.H.; Airaksinen, K.E.J.; Seppänen, T.; Huikuri, H.V. Effects of exercise and passive head-up tilt on fractal and complexity properties of heart rate dynamics. Am. J. Physiol. Circ. Physiol. 2001, 280, H1081–H1087.
  54. Mercuro, G.; Panzuto, M.G.; Bina, A.; Leo, M.; Cabula, R.; Petrini, L.; Pigliaru, F.; Mariotti, S. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin- suppressive therapy with levothyroxine: Effect of individual dose tailoring. J. Clin. Endocrinol. Metab. 2000, 85, 159–164.
  55. Biondi, B.; Fazio, S.; Cuocolo, A.; Sabatini, D.; Nicolai, E.; Lombardi, G.; Salvatore, M.; Saccà, L. Impaired cardiac reserve and exercice capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab. 1996, 81, 4224–4228.
  56. Olson, B.R.; Klein, I.; Benner, R.; Burdett, R.; Trzepacz, P.; Levey, G.S. Hyperthyroid Myopathy and the Response to Treatment. Thyroid 1991, 1, 137–141.
  57. Byrne, E.A.; Fleg, J.L.; Vaitkevicius, P.V.; Wright, J.; Porges, S.W. Role of aerobic capacity and body mass index in the age-associated decline in heart rate variability. J. Appl. Physiol. 1996, 81, 743–750.
  58. Tsuji, H.; Venditti FJJr Manders, E.S.; Evans, J.C.; Larson, M.G.; Feldman, C.L.; Levy, D. Determinants of heart rate variability. J. Am. Coll. Cardiol. 1996, 28, 1539–1546.
  59. Pfeifer, M.A.; Weinberg, C.; Cook, D.; Best, J.; Reenan, A.; Halter, J.B. Differential changes of autonomic nervous system function with age in man. Am. J. Med. 1983, 75, 249–258.
  60. Wang, W.; Rong, M. Cardiac sympathetic afferent reflexes in heart failure. Heart Fail. Rev. 2000, 5, 57–71.
  61. Askin, L.; Cetin, M.; Turkmen, S. Ambulatory blood pressure results and heart rate variability in patients with premature ventricular contractions. Clin. Exp. Hypertens. 2018, 40, 251–256.
  62. de Andrade, P.E.; do Amaral, J.A.T.; Paiva, L.D.S.; Adami, F.; Raimudo, J.Z.; Valenti, V.E.; Abreu, L.C.; Raimundo, R.D. Reduction of heart rate variability in hypertensive elderly. Blood Press. 2017, 26, 350–358.
  63. Schroeder, E.B.; Liao, D.; Chambless, L.E.; Prineas, R.J.; Evans, G.W.; Heiss, G. Hypertension, blood pressure, and heart rate variability: The atherosclerosis risk in communities (ARIC) study. Hypertension 2003, 42, 1106–1111.
  64. Al-Trad, B.A.; Mansi, M.; Alaraj, M.; Al-Hazimi, A. Cardiac autonomic dysfunction in young obese males is not associated with disturbances in pituitary-thyroid axis hormones. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 1689–1695.
  65. Mustafa, G.; Kursat, F.M.; Ahmet, T.; Alparslan, G.F.; Omer, G.; Sertoglu, E.; Erkan, S.; Ediz, Y.; Turker, T.; Ayhan, K. The relationship between erythrocyte membrane fatty acid levels and cardiac autonomic function in obese children. Rev. Port. Cardiol. 2017, 36, 499–508.
  66. Wu, E.C.-H.; Huang, Y.-T.; Chang, Y.-M.; Chen, I.-L.; Yang, C.-L.; Leu, S.-C.; Su, H.-L.; Kao, J.-L.; Tsai, S.-C.; Jhen, R.-N.; et al. The Association between Nutritional Markers and Heart Rate Variability Indices in Patients Undergoing Chronic Hemodialysis. J. Clin. Med. 2019, 8, 1700.
  67. Nevill, A.M.; Stewart, A.; Olds, T.; Holder, R. Relationship between adiposity and body size reveals limitations of BMI. Am. J. Phys. Anthr. 2005, 129, 151–156.
  68. Zeng, Q.; Dong, S.Y.; Sun, X.N.; Xie, J.; Cui, Y. Percent body fat is a better predictor of cardiovascular risk factors than body mass index. Braz. J. Med. Biol. Res. 2012, 45, 591–600.
  69. Esco, M.R.; Williford, H.N.; Olson, M.S. Skinfold Thickness is Related to Cardiovascular Autonomic Control as Assessed by Heart Rate Variability and Heart Rate Recovery. J. Strength Cond. Res. 2011, 25, 2304–2310.
  70. Millis, R.M.; Austin, R.E.; Hatcher, M.D.; Bond, V.; Faruque, M.U.; Goring, K.L.; Hickey, B.M.; DeMeersman, R.E. Association of body fat percentage and heart rate variability measures of sympathovagal balance. Life Sci. 2010, 86, 153–157.
  71. Brunová, J.; Kasalický, P.; Lánská, V. The assessment of body composition using DEXA in patients with thyroid dysfunction. Cas. Lek. Cesk. 2007, 5, 497–502.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback